This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Your Vote Counts: Who Is the Worst Biotech CEO of 2011?

Looming patent expirations on key Gilead HIV drugs have weighed heavily on the company's stock price. Martin deserves credit for building Gilead into the dominant HIV drug company but he's also at fault for letting that coveted franchise stagnate.

Multiple acquisitions and partnerships in other disease areas have proven to be expensive failures. Most glaringly, Gilead's efforts to develop its own Hep C drugs have gone nowhere, a corporate embarrassment given Gilead's supposed antiviral drug expertise.

Everyone can agree that Gilead needed to do something to reinvigorate growth. But is gambling $11 billion on a risky Pharmasset acquisition the best idea Martin could come up with? Right now, the deal smacks of desperation, which is enough to land Martin a spot as a worst biotech CEO nominee.

Mitch Gold, Dendreon

One year a champ, the next a chump. That's the predicament in which Dendreon CEO Mitch Gold finds himself exiting 2011. The huzzahs of 2010 -- FDA's approval of Provenge, unbound optimism for the launch of the first prostate cancer immunotherapy, not to mention winning TheStreet's Best Biotech CEO of the Year Award -- are now tattered memories.

Gold's 2011 has been a living nightmare largely of his own making. He mispriced Provenge, overestimated patient demand for the cancer immunotherapy and was wholly unprepared to deal effectively with the inevitable reimbursement concerns and questions that come with a new and novel therapy.

As a result, Dendreon's stock and reputation are in tatters. Shareholders (those who stuck with the company) are P.O.'d, some are calling for Gold's ouster. Provenge, once the most talked-about prostate cancer therapy, is at risk of falling into irrelevancy due to competing drugs that are easier to use and just as effective.

Remember when other companies wanted to be "the next Dendreon"? Today, not so much, which is why placing Gold on this list was one of the easiest decisions I've made in a long time.

Joseph Zakrzewski, Amarin

A stunning inability (or unwillingness) to communicate with investors lands Zakrzewski a worst CEO nomination.

Exhibit A: Zakrzewsi opens his mouth to titillate shareholders with the possibility of a lucrative takeout. Naturally, this sets expectations sky high. Said expectations crash and burn when no deal is delivered, taking Amarin's stock price down with it.
2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ELN $0.00 0.00%
AMRN $1.38 -4.80%
DNDN $0.06 -6.02%
GILD $85.13 -1.80%
MNKD $0.97 -0.75%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs